(Q38008723)

26 August 2017

title

Novel targeted agents for the treatment of advanced breast cancer (English)

1 reference

26 August 2017

Máximo de la Vega

1

1 reference

26 August 2017

Enrique Díaz-Cantón

series ordinal

2

1 reference

26 August 2017

Ricardo H Alvarez

series ordinal

3

1 reference

26 August 2017

publication date

1 May 2012

1 reference

Future Medicinal Chemistry

26 August 2017

published in

1 reference

26 August 2017

volume

4

1 reference

26 August 2017

issue

7

1 reference

26 August 2017

page(s)

893-914

1 reference

Untangling the ErbB signalling network

26 August 2017

cites work

1 reference

A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling

21 January 2018

1 reference

Specificity within the EGF family/ErbB receptor family signaling network

21 January 2018

1 reference

Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers

21 January 2018

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients

21 January 2018

1 reference

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

21 January 2018

1 reference

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study

21 January 2018

1 reference

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer

21 January 2018

1 reference

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

21 January 2018

1 reference

Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories

21 January 2018

1 reference

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study

21 January 2018

1 reference

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

21 January 2018

1 reference

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

21 January 2018

1 reference

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer

21 January 2018

1 reference

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

Adenoid cystic carcinoma, low-differentiation carcinoma, squamous cell carcinoma: a rare evolution of a tracheal malignancy within 27 years.

21 January 2018

1 reference

Growth factor receptor interplay and resistance in cancer

21 January 2018

1 reference

Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination

21 January 2018

1 reference

Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2

21 January 2018

1 reference

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer.

21 January 2018

1 reference

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

21 January 2018

1 reference

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

Cancer vaccines: between the idea and the reality

21 January 2018

1 reference

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer

21 January 2018

1 reference

Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer

21 January 2018

1 reference

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

21 January 2018

1 reference

Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation

21 January 2018

1 reference

Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.

21 January 2018

1 reference

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

21 January 2018

1 reference

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

21 January 2018

1 reference

Insulin-like growth factors and neoplasia.

21 January 2018

1 reference

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.

21 January 2018

1 reference

Prognostic value of vascular endothelial growth factor in breast cancer

21 January 2018

1 reference

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

21 January 2018

1 reference

The biology of VEGF and its receptors

21 January 2018

1 reference

The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies.

21 January 2018

1 reference

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

Bevacizumab treatment for advanced breast cancer

21 January 2018

1 reference

A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer

21 January 2018

1 reference

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

21 January 2018

1 reference

Bevacizumab added to neoadjuvant chemotherapy for breast cancer

21 January 2018

1 reference

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

21 January 2018

1 reference

21 January 2018

1 reference

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

21 January 2018

1 reference

ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein

21 January 2018

1 reference

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

21 January 2018

1 reference

Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo

21 January 2018

1 reference

Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.

21 January 2018

1 reference

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors

21 January 2018

1 reference

Recurrent priapism related to oxaliplatin infusion

21 January 2018

1 reference

A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium

21 January 2018

1 reference

Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?

21 January 2018

1 reference

Exploiting the PI3K/AKT pathway for cancer drug discovery

21 January 2018

1 reference

The phosphoinositide 3-kinase pathway

21 January 2018

1 reference

Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer

21 January 2018

1 reference

Mechanisms and consequences of activation of protein kinase B/Akt

21 January 2018

1 reference

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab

21 January 2018

1 reference

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

21 January 2018

1 reference

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

21 January 2018

1 reference

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?

21 January 2018

1 reference

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

21 January 2018

1 reference

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

21 January 2018

1 reference

Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands

21 January 2018

1 reference

Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast gro

21 January 2018

1 reference

Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate.

21 January 2018

1 reference

21 January 2018

A renaissance for SRC

1 reference

The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors

21 January 2018

1 reference

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

21 January 2018

1 reference

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy

21 January 2018

1 reference

From bench to clinic with apoptosis-based therapeutic agents

21 January 2018

1 reference

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

A review of PARP inhibitors: from bench to bedside

21 January 2018

1 reference

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

21 January 2018

1 reference

Unmeasured costs of a child's death: perceived financial burden, work disruptions, and economic coping strategies used by American and Australian families who lost children to cancer

21 January 2018

1 reference

Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor

21 January 2018

1 reference

Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib

21 January 2018

1 reference

A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer

21 January 2018

1 reference

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

21 January 2018

1 reference

A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy

21 January 2018

1 reference

Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4155/FMC.12.45

1 reference

26 August 2017

1 reference